Seeking Alpha

The FDA expects to miss its March 1 deadline for approving Zogenix's (ZGNX +13.2%) application...

The FDA expects to miss its March 1 deadline for approving Zogenix's (ZGNX +13.2%) application for its Zohydro painkiller. The FDA didn't provide a reason for the delay, which may last several weeks, but nor did it indicate that there are any problems with Zogenix's filing. In December, FDA advisors said Zohydro should only get approval once Zogenix has taken measures to help limit opioid abuse. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)